Baird International And Global Growth Funds Q2 2026 Contributors And DetractorsSeeking Alpha • 07/13/26
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reportsReuters • 06/29/26
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilitiesCNBC • 06/29/26
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already InvestedThe Motley Fool • 06/28/26
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and WebcastGlobeNewsWire • 06/25/26
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)GlobeNewsWire • 06/22/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNPRNewsWire • 06/11/26
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 06/10/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development OpportunitiesSeeking Alpha • 06/08/26
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDOGlobeNewsWire • 06/04/26
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)Zacks Investment Research • 06/01/26
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)Zacks Investment Research • 06/01/26
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 05/29/26
Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus OutbreakGlobeNewsWire • 05/28/26
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)Newsfile Corp • 05/25/26
Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud AllegationsNewsfile Corp • 05/25/26
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing LossGlobeNewsWire • 05/22/26